ArticleScience advances2020
Surface-anchored framework for generating RhD-epitope stealth red blood cells.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 70 citations in OpenAlex.
- Bioenzymatic single-cell microencapsulation for enhanced stem Cell therapy.Bioactive materials · 2026Article
- On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit-engineered cells.Science advances · 2026Article
- Blood Mechanical Intelligence: From Force Sensing to Precision Mechanomedicine.Research (Washington, D.C.) · 2026Review
- Sweet and sticky: increased cell adhesion through click-mediated functionalization of regenerative liver progenitor cells.Communications biology · 2025Article
- A decadal profile of RhD-negative blood donors in Chongqing, China: demographics, phenotypic diversity, and donation behavior.Frontiers in public health · 2025Article
- Improving normothermic machine perfusion and blood transfusion through biocompatible blood silicification.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Red Blood Cell Membrane-Coated Nanoparticles Enable Incompatible Blood Transfusions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Engineering Synthetic Erythrocytes as Next-Generation Blood Substitutes.Advanced functional materials · 2024Article
- Effects ofAnimals : an open access journal from MDPI · 2024Article
- Organismal Function Enhancement through Biomaterial Intervention.Nanomaterials (Basel, Switzerland) · 2024Review
- Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications.Theranostics · 2024Review
- Advancing cell surface modification in mammalian cells with synthetic molecules.Chemical science · 2023Review
- Generation of Rh D-negative blood using CRISPR/Cas9.Cell proliferation · 2023Article
- Material-engineered bioartificial microorganisms enabling efficient scavenging of waterborne viruses.Nature communications · 2023Article
- Biohybrid materials: Structure design and biomedical applications.Materials today. Bio · 2022Article
- Engineering living cells with cucurbit[7]uril-based supramolecular polymer chemistry: from cell surface engineering to manipulation of subcellular organelles.Chemical science · 2022Article
- Nematode surface functionalization with hydrogel sheaths tailoredMaterials today. Bio · 2022Article
- Engineered osteoclasts as living treatment materials for heterotopic ossification therapy.Nature communications · 2021Article
- Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers.International journal of molecular sciences · 2021Review
- Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics.Pharmaceutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhesus D (RhD) is one of the most important immunogenic antigens on red blood cells (RBCs). However, the supply of RhD-negative blood frequently faces critical shortages in clinical practice, and the positive-to-negative transition of the RhD antigen remains a great challenge. Here, we developed an alternative approach for sheltering the epitopes on RhD-positive RBCs using a surface-anchored framework, which is flexible but can achieve an optimal shield effect with minimal physicochemical influence on the cell. The chemical framework completely obstructed the RhD antigens on the cell surface, and the assessments of both blood transfusion in a mouse model and immunostimulation with human RhD-positive RBCs in a rabbit model confirmed the RhD-epitope stealth characteristics of the engineered RBCs. This work provides an efficient methodology for improving the cell surface for universal blood transfusion and generally indicates the potential of rationally designed cell surface engineering for transfusion and transplantation medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.